Last updated 2026-07-27
TL;DR
People on off-label sirolimus typically get baseline and periodic bloodwork covering lipids, CBC, fasting glucose/HbA1c, kidney and liver function, and sometimes a trough drug level. There's no FDA-approved monitoring schedule for longevity use, so protocols come from transplant dosing extrapolated down. Expect a baseline panel, a recheck at 6 to 8 weeks, then every 3 to 6 months if stable.
What blood tests do people on sirolimus actually get?
Most off-label protocols borrow their monitoring lists from transplant medicine, then trim them down. The core panel people ask about includes a complete blood count (CBC), a metabolic panel covering kidney and liver function, electrolytes and glucose, a fasting lipid panel, and sometimes HbA1c. Some clinicians add a sirolimus trough level, drawn right before the next dose, though trough monitoring is a transplant-medicine habit and its relevance to weekly or biweekly longevity dosing is genuinely unsettled. The FDA label for Rapamune (sirolimus) requires trough monitoring in transplant patients because the drug has a narrow therapeutic index and interacts with dozens of other medications; the label states clinicians should monitor "whole blood trough concentrations" especially in patients with liver impairment, on interacting drugs, or when switching formulations [1]. That requirement exists for people on daily sirolimus at transplant-rejection-preventing doses, taken alongside other immunosuppressants. It was never built for someone taking 5-6mg once a week for anti-aging purposes, so providers who order troughs for longevity patients are extrapolating, not following label guidance. Lipids matter because sirolimus reliably raises triglycerides and LDL cholesterol in a meaningful fraction of users. In the original Rapamune trials, hypercholesterolemia and hypertriglyceridemia were among the most common adverse events reported, occurring in a large minority of transplant patients on the drug [1]. Whether the same happens at low, intermittent longevity doses is not established with the same rigor, but it's the single most consistent lab abnormality clinicians report anecdotally, so a fasting lipid panel before starting and again at the first recheck is close to universal practice. CBC catches the drug's known effects on blood counts: anemia, low platelets, and low white cell counts have all been reported in sirolimus-treated transplant patients [1]. None of these are common at low intermittent doses in otherwise healthy people. But they're cheap to rule out, and cheap to catch early if they happen.
How often should you get bloodwork on sirolimus?
There's no FDA-sanctioned schedule for longevity use, since the drug isn't approved for that indication at all. A reasonable, commonly used cadence is baseline before starting, a recheck at 6 to 8 weeks, then every 3 to 6 months once values look stable. Baseline testing matters more than people think. You want to know your starting lipids, kidney function, and blood counts before you introduce a drug that can shift all three, so that any post-dosing change has a reference point instead of a guess. Skipping baseline labs and just starting the drug means you'll never know if a later abnormal result is new or was always there. The 6 to 8 week recheck lines up with roughly 5 to 6 dosing cycles for a weekly protocol, giving lipids and glucose time to show a trend rather than a one-off fluctuation. If everything's stable at that point, quarterly to twice-yearly testing is what most providers who prescribe sirolimus off-label settle into. If lipids or glucose drift up, or if a dose increase happens, more frequent testing (back to every 6 to 8 weeks) is the sensible move until things settle again. Anyone adjusting their own dose without physician input should know that changing frequency or amount resets this clock. A Sirolimus Rx dosage calculator can help estimate a starting point based on weight and intended interval, but it doesn't replace a lab-informed decision about whether your body is tolerating the drug.
Why does sirolimus affect cholesterol and triglycerides?
Sirolimus inhibits mTOR complex 1, which sits at the center of cellular lipid metabolism, and blocking it changes how the liver handles fat and cholesterol trafficking. The practical result, seen consistently in transplant patients, is elevated LDL cholesterol and triglycerides, sometimes sharply. The Rapamune prescribing information lists hypercholesterolemia and hyperlipidemia as adverse reactions occurring in a substantial share of treated transplant patients, common enough that the label recommends monitoring lipids and treating clinically significant elevations, including with lipid-lowering therapy where indicated [1]. This is at standard transplant doses (daily dosing to maintain therapeutic troughs), not the pulsed weekly low doses common in off-label longevity protocols, so the actual magnitude of lipid change at low intermittent doses is less well characterized. Case reports and small case series in the longevity-adjacent literature (not registered trials) suggest lipid changes at low doses are milder and often reversible, but nobody has run the large controlled human study that would nail down a number. The honest position: expect lipids to be the metabolic parameter most likely to move. Expect it to be reversible if caught and if the dose is adjusted or stopped. And don't skip the fasting lipid panel that would catch it early.
Can sirolimus affect blood sugar or cause diabetes-like changes?
Yes, in some people, and this is one of the more counterintuitive risks given how often mTOR inhibition is framed as metabolically beneficial in mouse studies. New-onset diabetes after transplant is a recognized risk with sirolimus and other mTOR inhibitors, and the mechanism (impaired insulin secretion and increased insulin resistance in peripheral tissue) is described in the clinical transplant literature [2]. This matters because a lot of the enthusiasm for rapamycin's longevity potential comes from mouse data showing improved metabolic and immune markers, alongside the well-established lifespan extension from the NIA Interventions Testing Program (ITP), where rapamycin extended median lifespan in genetically heterogeneous mice by roughly 9% to 14% in males and up to about 18% to 21% in females depending on the cohort and starting age of treatment [3]. Those are real, replicated, multi-site results, among the strongest findings in the entire mouse lifespan-extension literature. But the ITP measures survival, not human glucose tolerance, and the metabolic side effects seen in transplant patients on chronic daily dosing don't necessarily translate cleanly to weekly low-dose human use, in either direction, good or bad. A fasting glucose or HbA1c at baseline and at each recheck is the practical way to catch this early. Someone with pre-existing insulin resistance or a family history of type 2 diabetes should watch this parameter more closely than someone metabolically healthy going in.
Does sirolimus suppress the immune system, and how would blood work show that?
Sirolimus is FDA-approved as an immunosuppressant specifically to prevent organ transplant rejection, which means immune suppression isn't a side effect, it's the intended mechanism at approved doses [1]. At the low intermittent doses used off-label for longevity, the degree of immune suppression is much less clear, and this is one of the biggest unresolved questions in the whole space. A CBC with differential is the standard way to look for it in bloodwork: a drop in white blood cell count, especially lymphocytes, is the lab signature of immune suppression. The Rapamune label lists leukopenia among reported adverse events in transplant patients [1]. Whether weekly low-dose users show any measurable change in white counts is not something a completed human trial has answered; what exists is smaller observational data and self-report, not registry-level evidence. The practical risk isn't usually a lab number, it's clinical: more frequent or slower-healing infections, delayed wound healing, or reactivation of latent viruses. Anyone with a history of chronic infections, on other immunosuppressive medication, or with a compromised immune system for any reason should treat this as a real contraindication conversation with a prescriber, more than a labs-look-fine question. See Sirolimus Rx contraindications for the fuller list of who should not be taking this drug off-label at all.
What about mouth ulcers, are they something bloodwork catches?
No. Mouth ulcers (technically aphthous stomatitis) are one of the most commonly reported side effects of sirolimus, showing up in a meaningful share of transplant patients on the drug according to the Rapamune label [1], and they're also one of the most commonly self-reported side effects among off-label longevity users. There's no blood test for this. You either get them or you don't, and they tend to show up in the first few weeks of a new dose or dose increase. Management is symptomatic: some people find dose reduction resolves it, some rotate to a less frequent interval, some just tolerate it if it's mild. It's not dangerous, but it's the side effect most likely to actually make someone stop the drug, more so than any lab abnormality, because it's uncomfortable and immediate while lipid or glucose changes are silent until you test for them. For a fuller rundown of this and other side effects reported over months to years of use, see Sirolimus Rx long term side effects.
Is there an FDA-approved lab monitoring schedule for longevity use of sirolimus?
No, and there can't be, because sirolimus has no FDA approval for longevity, anti-aging, or lifespan extension in humans at all. Its approvals cover kidney transplant rejection prophylaxis (Rapamune) and specific conditions like lymphangioleiomyomatosis and PEComa (Fyarro) and facial angiofibromas from tuberous sclerosis (Hyftor) [1][4]. Every monitoring schedule you'll see for off-label longevity dosing, including the one above, is a clinical extrapolation built by individual prescribers from transplant-medicine practice, not a labeled or agency-endorsed protocol. This distinction matters more than it sounds. It means the interval, the exact panel, and the trough target (if any) vary by prescriber, and none of it is backed by a completed human trial measuring whether it actually prevents harm or predicts benefit in low-dose intermittent longevity users. The mouse data behind the longevity interest is strong and independently replicated, the human dosing and monitoring framework built on top of it is not.
What's the difference between monitoring sirolimus and monitoring rapamycin, is it the same drug?
Same molecule. Sirolimus is the generic/pharmacologic name; rapamycin is the original name given to the compound when it was isolated from Streptomyces hygroscopicus found in soil on Easter Island (Rapa Nui) in the 1970s, and both terms refer to the identical active compound [5]. Brand names layered on top (Rapamune for the oral solution and tablets, Fyarro for the nanoparticle albumin-bound IV formulation, Hyftor for the topical gel) are different formulations of the same molecule, approved for different indications, and the monitoring implications differ by formulation and route. An oral tablet or solution used off-label for longevity is monitored the way described above: periodic blood draws for lipids, metabolic panel, and CBC. A topical gel like Hyftor has essentially no systemic absorption at approved doses and doesn't carry the same bloodwork burden. If you see "rapamycin" and "sirolimus" used interchangeably in longevity forums and provider materials, that's accurate, not sloppy terminology, they're the same drug.
How does off-label longevity dosing differ from the dosing that was actually studied?
This is the crux of the whole conversation. The mouse data anchoring rapamycin's longevity reputation, the NIA Interventions Testing Program, used continuous dietary dosing (rapamycin mixed into food, delivered essentially daily) at doses calibrated for mice, starting in some cohorts as late as 9 months of age (roughly human late-30s equivalent) and still extending lifespan [3]. Human off-label protocols, by contrast, almost universally use once-weekly or once-every-two-weeks oral dosing at 3 to 10mg, a pattern chosen specifically to minimize the chronic immunosuppression and metabolic effects seen with daily transplant dosing, based on pharmacokinetic reasoning (long half-life, intermittent peak exposure) rather than on a completed human outcome trial. No randomized, placebo-controlled human trial has tested whether this weekly low-dose pattern extends human lifespan, slows a validated human aging biomarker at population scale, or even matches the mouse dosing's biological effect. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), run out of AFAR/UCLA-affiliated researchers, is one of the few dedicated human dosing-and-safety studies and it measured tolerability, frailty, and quality-of-life type outcomes over roughly 48 weeks, not lifespan, because a human lifespan trial would take decades and enormous scale to run . That's the gap: strong, replicated mouse survival data, and no completed human trial answering the same survival question, only smaller safety and biomarker studies of much shorter duration. For a full breakdown of what human evidence does and doesn't exist, see Sirolimus Rx results what the research shows, and for a critical look at the anecdotal claims circulating online, Sirolimus Rx before and after claims.
What lab values should worry you enough to stop or call a provider?
| Fasting triglycerides | Above 500 mg/dL | Pancreatitis risk rises sharply per NIH lipid guidance independent of sirolimus | |
|---|---|---|---|
| LDL cholesterol | Significant rise from baseline | Cardiovascular risk marker, sirolimus is a known contributor to lipid elevation [1] | |
| White blood cell count | Below normal reference range | Sign of immune suppression, infection risk | |
| Platelets | Below normal reference range | Bleeding risk, reported adverse effect of sirolimus [1] | |
| Fasting glucose / HbA1c | Rising trend or diabetic range | New-onset insulin resistance reported with mTOR inhibitors [2] | |
| Creatinine / eGFR | Significant rise from baseline | Kidney function, standard safety check on any long-term medication | Any of these moving in the wrong direction across two consecutive tests, more than one noisy result, is a real signal to talk to whoever's prescribing about dose reduction, a longer interval between doses, or stopping altogether. One abnormal value in isolation is often noise; a trend across two or three testing intervals is the thing to act on. |
A few thresholds are worth knowing in plain terms, though none of these are longevity-specific guidelines, they're extrapolated from transplant monitoring and general lipid/metabolic risk thresholds. | Lab value | General concern threshold | Why it matters |
Where should you actually get this bloodwork done, and who should order it?
Standard labs like a CBC, metabolic panel, and fasting lipid panel are available through any primary care provider, most direct-to-consumer lab services, and most telehealth platforms that prescribe sirolimus off-label. A sirolimus trough level is more specialized and typically needs to go through a lab set up for transplant-drug monitoring (most major reference labs, like Quest and LabCorp, offer it, but it needs to be specifically ordered, not part of a standard panel). The honest recommendation is to get bloodwork ordered and interpreted by a licensed provider who understands both the transplant pharmacology this drug comes from and the off-label context you're actually using it in, rather than ordering labs yourself and trying to interpret them without clinical guidance. Sirolimus Rx works with a provider-reviewed model, where a clinician evaluates whether sirolimus is appropriate, orders and reviews baseline and follow-up labs, and the prescription itself is filled through a licensed pharmacy partner, not compounded or manufactured by Sirolimus Rx itself. That structure exists specifically because interpreting a trough level or a creeping lipid trend against a backdrop of missing human outcome data is a judgment call, not a spreadsheet lookup. Before starting, it's worth reading up on who shouldn't be taking this drug at all regardless of labs looking fine, covered in Sirolimus Rx contraindications, and understanding sourcing quality if the prescription is being filled through a compounding pathway, covered in Sirolimus Rx purity and testing.
Frequently asked questions
What blood tests are needed before starting sirolimus?
A baseline panel typically includes a CBC, a metabolic panel (kidney and liver function, glucose), and a fasting lipid panel. Some providers add HbA1c. This baseline lets you and your provider tell whether any later change is new or was always present, which matters given sirolimus's known effects on lipids and blood counts reported in the Rapamune label [1].
How often should I get bloodwork while on sirolimus?
A common off-label cadence is baseline, a recheck at 6 to 8 weeks, then every 3 to 6 months if values are stable. There's no FDA-mandated schedule for longevity use since the drug isn't approved for that indication; this interval is extrapolated from transplant monitoring practice, not from a longevity-specific trial.
Does sirolimus raise cholesterol?
Often, yes. Hypercholesterolemia and hypertriglyceridemia are among the most common adverse events reported in the Rapamune prescribing information for transplant patients [1]. Whether the same magnitude occurs at low weekly longevity doses is less well studied, but a fasting lipid panel at baseline and follow-up is standard practice to catch it early.
Can sirolimus cause diabetes or raise blood sugar?
New-onset diabetes after transplant is a recognized risk with sirolimus and other mTOR inhibitors, driven by reduced insulin secretion and increased insulin resistance [2]. At low intermittent longevity doses the risk magnitude isn't established by a completed trial, so fasting glucose or HbA1c monitoring is a reasonable precaution, especially for anyone with pre-existing risk factors.
Do I need a sirolimus trough level test for off-label longevity use?
Trough monitoring is required by the FDA label for transplant patients on daily dosing because of the drug's narrow therapeutic index and interaction risk [1]. For weekly off-label longevity dosing, trough testing is not standardized; some prescribers order it, others don't. It's a clinical extrapolation, not a labeled requirement.
Are sirolimus and rapamycin the same drug for testing purposes?
Yes. Sirolimus and rapamycin are the identical molecule, originally isolated from a soil bacterium found on Easter Island [5]. Blood testing and monitoring considerations are the same regardless of which name is used, though different brand formulations (Rapamune, Fyarro, Hyftor) have different absorption profiles and monitoring implications.
Will mouth ulcers show up in bloodwork?
No. Mouth ulcers (aphthous stomatitis) are a commonly reported sirolimus side effect [1] but there's no blood test for them. They're diagnosed by symptom and appearance, typically in the first weeks of starting or increasing a dose, and usually managed by dose adjustment rather than lab-guided treatment.
Does sirolimus weaken the immune system at low longevity doses?
Sirolimus is FDA-approved as an immunosuppressant at transplant doses, where immune suppression is the intended effect [1]. At low weekly longevity doses, the degree of immune suppression hasn't been measured in a completed large human trial. A CBC with differential can flag falling white blood cell counts, but clinical infection risk is the more relevant real-world signal to watch.
Is there a human trial showing sirolimus extends lifespan?
No completed human lifespan trial exists. The strongest evidence is in mice, from the NIA Interventions Testing Program, which found consistent, replicated lifespan extension across multiple study sites [3]. Human studies like PEARL have measured safety, tolerability, and frailty-related markers over roughly a year, not survival, because a lifespan trial in humans would take decades [6].
What lab result should make me stop taking sirolimus?
Triglycerides climbing above roughly 500 mg/dL raise pancreatitis risk independent of the drug and warrant immediate attention [7]. A falling white count or platelet count, a rising creatinine trend, or a clear upward trend in fasting glucose across two or more tests are all reasons to contact your prescriber about dose adjustment or stopping.
Can I just order my own bloodwork without a prescriber?
You can order many of these tests directly through consumer lab services, but interpreting a trough level, a lipid trend, or an early glucose shift against the backdrop of missing longevity-specific human data is a clinical judgment call. A provider who understands both transplant pharmacology and off-label longevity dosing is worth involving rather than self-interpreting results.
How much does sirolimus monitoring bloodwork typically cost?
Costs vary widely by lab and insurance status; a CBC, metabolic panel, and lipid panel through a standard reference lab commonly runs somewhere in the range of $50 to $200 out of pocket without insurance, though exact pricing depends on the lab, region, and whether it's bundled with a provider visit. A specialized trough level typically costs more and isn't part of a standard panel.
Sources
- American Journal of Transplantation / clinical transplant literature on new-onset diabetes after transplant with mTOR inhibitors: Sirolimus and other mTOR inhibitors are associated with new-onset diabetes after transplant via impaired insulin secretion and increased insulin resistance
- NIA Interventions Testing Program, rapamycin lifespan results: Rapamycin extends median lifespan in genetically heterogeneous mice across multiple test sites, with effects seen even when started later in life
- NIH National Library of Medicine / PubChem, rapamycin compound origin: Rapamycin was originally isolated from Streptomyces hygroscopicus found in soil samples from Easter Island (Rapa Nui)
- PEARL Trial (Participatory Evaluation of Aging with Rapamycin for Longevity), AFAR-affiliated study: A human trial measuring tolerability, safety, and frailty-related outcomes of low-dose rapamycin over approximately 48 weeks, not lifespan
- National Heart, Lung, and Blood Institute, lipid disorders / triglyceride risk guidance: Elevated triglycerides above very high thresholds raise pancreatitis risk independent of cause